Red-Flag Signs May Indicate Early-Onset Colorectal Cancer
Abdominal pain, rectal bleeding, diarrhea, and iron deficiency anemia seen up to 2 years before diagnosis.
Diagnosis & Disease Information
Recent 2023 FDA Approvals
Recent FDA approvals include treatments for chronic migraine, type 1 diabetes, blood cancers, tardive dyskinesia and chorea associated with Huntington disease, vasomotor symptoms of menopause, pain and fever, and Fabry disease.
Cancer Patients With Diabetes May Have Worse Outcomes on ICIs
Cancer patients with type 2 diabetes may have worse survival outcomes on immune checkpoint inhibitor therapy, a new study suggests.
Screening Recommendations Updated for Increased Breast Cancer Risk
Women with higher-than-average breast cancer risk, especially Black and Ashkenazi Jewish women, should start screening at younger age.
Risk of Drug-Drug Interactions in Patients With HIV and Cancer
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
Characteristics, Treatment Options for Patients With Advanced Gynecologic Cancers
A presentation at the 2023 ONA Summit reviewed diagnosis and treatment recommendations for uterine, ovarian, and endometrial cancers.
Achieving, Managing Patient Care During Maintenance Therapy for AML
The unique needs of patients with AML undergoing maintenance therapy, including care disparities and challenges, are discussed at the 2023 ONA Summit.
Updates in Targeted Therapies, Management Strategies for Non-Small Cell Lung Cancer
In an oral presentation at the 2023 ONA Summit, a thoracic oncology nurse practitioner reviewed the advances in the treatment of NSCLC and management of related adverse effects.
Advanced Gastric and Colorectal Cancer Diagnosis and Treatment
Management strategies aimed at improving outcomes in patients with CRC and gastric cancer were presented at the 2023 ONA Summit.
New Treatments, New Challenges in the Treatment of Bladder and Renal Cancers
A discussion of new treatment options that have improved prognosis for patients with bladder cancer and renal cell carcinoma is the focus of a presentation at the 2023 ONA Summit.
- Loading...
Loading...
Next post in Oncology Information Center
Loading... 
Loading...